Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate

Toxicology

Volumn 167, Issue 1, 2001, Pages 83-98

  Funk, Christoph ^a   Pantze, Michael ^a   Jehle, Linda ^a   Ponelle, Christiane ^a   Scheuermann, Gerd ^a   Lazendic, Mirjana ^a   Gasser, Rodolfo ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

ABC transporter; Bile acids; Cholestasis; Drug drug interactions; Hepatotoxicity; Sulfotransferase; Troglitazone

Indexed keywords

BILE ACID; GLIBENCLAMIDE; SULFUR DERIVATIVE; TAUROCHOLIC ACID; TROGLITAZONE; TROGLITAZONE SULFATE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE FLOW; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; IC 50; INTRAHEPATIC CHOLESTASIS; LIVER CELL MEMBRANE; LIVER INJURY; LIVER TOXICITY; MALE; MEMBRANE VESICLE; NONHUMAN; PRIORITY JOURNAL; RAT; SEX DIFFERENCE;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BILE ACIDS AND SALTS; BILIARY TRACT; BIOLOGICAL TRANSPORT, ACTIVE; CHOLESTASIS, INTRAHEPATIC; CHROMANS; CYTOSOL; FEMALE; GLYBURIDE; HYPOGLYCEMIC AGENTS; LIVER; MALE; RATS; RATS, WISTAR; SEX FACTORS; SULFATES; TAUROCHOLIC ACID; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0035813014     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-483X(01)00460-7     Document Type: Article

References (44)

1. Hepatobiliary transport: Molecular mechanisms of development and cholestasis
2. Sulindac is excreted into bile by a canalicular bile salt pump and undergoes a cholehepatic circulation in rats
3. Biochemical separation of Na+, K+-ATPase from a 'purified' light density, 'canalicular'-enriched plasma membrane fraction from rat liver
4. Troglitazone: An antidiabetic agent
5. Comparative hepatotoxicity of cholic acid, deoxycholic acid and lithocholic acid in the rat: In vivo and in vitro studies
6. Histopathology of cholestasis
7. Tissue-specific expression of rat sulfotransferase messenger RNAs
8. Drug-induced cholestasis
9. Extrahepatic obstructive cholestasis reverses the bile salt secretory polarity of rat hepatocytes
10. Subacute hepatic failure associated with a new antidiabetic agent, troglitazone: A case report with autopsy examination
11. Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity. In vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat
12. The sister P-glycoprotein mediates ATP-dependent taurocholate (TCA) transport
13. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone
14. The colorimetric determination of leucine aminopeptidase in urine and serum of normal subjects and patients with cancer and other diseases
15. Induction of mitochondrial permeability transition as a mechanism of liver injury during cholestasis: A potential role for mitochondrial proteases
16. Control of hepatic proteolysis by amino acids. The role of cell volume
17. Severe hepatotoxicity associated with troglitazone
18. Age- and sex-related changes of sulfotransferase activities in the rat
19. Sulfotransferases
20. The human phenolsulfotransferase polymorphism is determined by the level of expression of the enzyme protein
21. Inhibition by cyclosporin A of adenosin triphosphate-dependent transport from the hepatocyte into bile
22. Disposition and metabolism of the new oral antidiabetic drug troglitazone in rats, mice and dogs
23. Studies of relationships among bile flow, liver plasma membrane NaK-ATPase, and membrane microviscosity in the rat
24. Fatal toxic intrahepatic cholestasis secondary to glibenclamide
25. Clinical pharmacokinetics of troglitazone
26. Properties of the canalicular bile acid transport system in rat liver
27. Structural and functional polarity of canalicular and basolateral plasma membrane vesicles isolated in high yield from rat liver
28. Cellular mechanisms of intrahepatic cholestasis
29. Troglitazone-induced hepatic failure leading to liver transplantation
30. Pharmacokinetics of troglitazone, PPAR-gamma antagonist, in patients with hepatic insufficiency
31. Genetic polymorphism in human liver phenol sulfotransferases involved in the bioactivation of N-hydroxy derivatives of carcinogenic arylamines and heterocyclic amines
32. Acute troglitazone action in isolated perfused rat liver
33. Validation of a recording spectrophotometric method for measurement of membrane-associated Mg- and Na/K-ATPase activity
34. Drug disposition as determined by the interplay between drug- transporting and drug-metabolizing systems
35. An autopsy case of troglitazone-induced fulminant hepatitis
36. The use of perfusion of liver and other organs for the study of microsomal electron-transport and cytochrome P-450 systems
37. Measurement of protein using bicinchoninic acid
38. Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver
39. ATP-dependent bile-salt transport in canalicular rat liver plasma-membrane vesicles
40. Molecular pathogenesis of cholestasis
41. Preparation and properties of partially purified cytochrome P-450 and reduced nicotinamide adenine dinucleotide phosphate-cytochrome P-450 reductase from rabbit liver microsomes
42. ATP dependent taurocholate transport in canalicular and basolateral plasma membrane vesicles isolated from human liver
43. Isolation and characterization of canalicular and basolateral plasma membrane fractions from human liver
44. Mechanisms for xenobiotic transport in biological membranes